Phillips adds Elanco flea and tick brands to retail network
Bottom line
Phillips Pet Food & Supplies said it has entered a distribution partnership with Elanco Animal Health, making Elanco’s over-the-counter flea and tick portfolio available to independent pet retailers through Phillips’ distribution network nationwide. The August 6, 2026, announcement names Seresto, K9 Advantix II, Advantage II, and Cheristin among the products now available through Phillips, which said the move is meant to help retailers add recognized parasite-control brands to routine orders. Phillips is also in the middle of a broader expansion push: earlier in 2026 it announced a strategic joint venture with Central Garden & Pet, and its latest company materials say it now operates 24 distribution centers across the U.S. (phillipspet.com)
Why it matters: For veterinary professionals, the deal is another sign that Elanco is leaning harder into retail distribution for parasiticides, especially in the OTC channel. Elanco has told investors it added new U.S. retail customers for parasiticides in 2026, and company materials describe a leading position in the U.S. OTC flea and tick market, anchored by Seresto and the Advantage family. Wider independent retail availability could improve access for pet parents shopping outside clinics, but it also raises the importance of clear veterinary guidance on product selection, adherence, species-specific safety, and when OTC prevention may not be the best fit. (investor.elanco.com)
What to watch: Watch whether Phillips’ expanded reach helps Elanco deepen physical distribution in independent pet retail ahead of the next flea and tick season, and whether that changes competitive pressure on clinic-dispensed preventives. (sec.gov)
Phillips Pet Food & Supplies has added Elanco Animal Health to its national distribution lineup, giving independent pet retailers access to Elanco’s OTC flea and tick products through Phillips’ network. In the August 6, 2026, announcement, Phillips said the partnership covers Seresto, K9 Advantix II, Advantage II, and Cheristin, and positions those brands for broader placement in independent stores nationwide. (phillipspet.com)
The move fits into a larger reshaping of pet health distribution. Phillips has been expanding its scale and reach this year, including an April 2026 announcement of a strategic joint venture with Central Garden & Pet. At the same time, Elanco has been emphasizing omnichannel growth in pet health, particularly around retail access for parasiticides. In its 2025 annual report, Elanco said it sells pet health products through distributors, retailers, and veterinarians, and noted that Seresto and the Advantage family are key products offered across those channels. (phillipspet.com)
Phillips framed the new agreement as a way to make high-demand parasite-control brands easier for independent retailers to stock. The company said Elanco’s OTC portfolio is now available through all Phillips distribution centers nationwide, and Chief Commercial Officer Jessica Morris said flea and tick is a category where consumers often shop by brand. That matters because Elanco’s own investor materials show just how central those brands remain to its retail strategy: in second-quarter 2026 results, the company reported $154 million in revenue from the Advantage family and $117 million from Seresto. (phillipspet.com)
Elanco has also been signaling that broader retail penetration is a priority. In first-quarter 2026 results, the company said it added Costco and Dollar General as new U.S. retail customers for parasiticides, and it launched Advantage Collar for Dogs into pet specialty, dollar, grocery, and mass retail channels. Investor materials released in 2026 describe Elanco as holding a 64% share of the U.S. OTC flea and tick market in the premium channel, while also pointing to “growing physical availability” and double-digit growth in distribution points as part of its playbook. (investor.elanco.com)
There was little independent expert commentary tied specifically to the Phillips announcement, but broader industry coverage points in the same direction. GlobalPETS reported this summer that Elanco has been reinforcing its OTC business through new retail customers, sales investment, and distribution partnerships, while Pet Insight’s recent distributor-marketplace coverage described Phillips as staying focused on the independent pet retailer even as consolidation changes the channel. Taken together, that suggests this is less a one-off vendor deal than part of a wider effort to build retail scale around established pet health brands. (globalpetindustry.com)
Why it matters: For veterinarians and practice teams, the partnership underscores the continued migration of some parasite prevention purchasing into retail settings. That doesn’t eliminate the clinic’s role; if anything, it sharpens it. As more pet parents encounter familiar OTC brands in independent stores, veterinary teams may need to spend more time helping clients compare OTC and prescription options, match products to parasite risk, household composition, age, species, and comorbidities, and reinforce proper use. The deal also keeps pressure on clinics to articulate the value of veterinary-recommended prevention in a market where convenience and brand recognition increasingly shape buying behavior. (phillipspet.com)
There’s also a reputational and safety backdrop worth remembering, especially around Seresto. Elanco has repeatedly defended the collar’s safety profile, and in 2022 the EPA said Seresto would remain registered after a multi-year review. Even so, the product has faced years of scrutiny, meaning veterinary professionals may continue fielding questions from pet parents as availability expands. That makes counseling, adverse-event awareness, and product-specific education especially important in both clinic and retail-adjacent conversations. (elanco.com)
What to watch: The next marker will be whether Phillips’ footprint translates into measurable gains in Elanco’s retail parasiticide distribution points or seasonal sales, particularly as the company continues to build out its OTC and clinic portfolios in parallel. Elanco’s disclosures show flea and tick products are highly seasonal, with roughly 70% of Seresto revenue and 60% of Advantage family revenue in 2025 generated in the first half of the year, so the commercial impact of this partnership may become clearer heading into the 2027 season. (sec.gov)